Skip to content

EMPOWER 3: Improving Palliative Care Health Literacy and Utilization

EMPOWER 3: Improving Palliative Care Health Literacy and Utilization

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04733469
Acronym
EMPOWER 3
Enrollment
172
Registered
2021-02-02
Start date
2021-03-31
Completion date
2026-08-31
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Neoplasm Malignant

Brief summary

Through this award, Michael Hoerger, PhD, MSCR, a psychologist at the Tulane Cancer Center in Louisiana, will lead a study called EMPOWER 3 designed to test an educational intervention to help patients understand palliative care, use it, and feel better emotionally and physically. Participants will be adults with serious cancer diagnoses. Participants will be randomized into two groups. Patients in the control group will get enhanced usual care, meaning standard cancer care and several additional healthcare-related brochures. Patients in the intervention group will get enhanced usual care plus an educational video developed by the investigators and other materials designed to increase understanding and use of palliative care. Family members of patients in the intervention group may also attend if desired. The investigators will track participants' understanding of palliative care, attitudes toward palliative care, symptoms over 6 months of follow-up, and palliative care utilization.

Interventions

The Multimedia Psychoeducational Intervention includes a multimedia educational video plus additional resources to reinforce the video content. The Multimedia Psychoeducational Intervention includes the following: * A multimedia educational video about palliative care that is individually tailored to each patient's level of education and health literacy * Take-home and online copies of the video for repeat viewing * A video summary * A question prompt list patients can use to ask clinicians more questions about palliative care * Contact information and brochures for local palliative care programs

BEHAVIORALEnhanced Usual Care

Enhanced Usual Care refers to usual care plus minor enhancement to improve quality and standardization. Enhanced Usual Care includes the following: * Usual care * A packet of flyers and handouts with general information on psychosocial oncology services derived from the American Society of Clinical Oncology (ASCO), Center to Advance Palliative Care (CAPC), and American Cancer Society (ACS)

Sponsors

Tulane University
Lead SponsorOTHER
American Cancer Society, Inc.
CollaboratorOTHER
University Medical Center-New Orleans
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult, age 18 or older 2. Meets criteria for 2a or 2b. 2a) The patient's doctor believes they may be appropriate for palliative cancer care OR 2b) The patient has a new diagnosis, recurrence, or progression of cancer in the past 90 days AND any of the following: * Advanced cancer, such as: * Lung Cancer: Stage IIIB or IV non-small cell, or extensive stage small cell * Breast Cancer: Stage IV * Gastrointestinal (GI) Cancers: Unresectable stage III or stage IV * Genitourinary (GU) Cancers: Stage IV * Melanoma: Stage IV * Hematologic Malignancies * Leukemia (e.g., acute myeloid leukemia \[AML\], acute lymphoblastic leukemia \[ALL\], chronic myeloid leukemia (CML), chronic lymphocytic leukemia \[CLL\]): advanced stage, treatment refractory, poor prognosis cell type or chromosomal abnormalities, older age * Lymphoma: Stage IV or treatment refractory Hodgkin's disease or non-Hodgkin's lymphoma Multiple Myeloma: elevated β2-microglobulin, albumin \<3.5, PCLI \>1%, CRP \>6µg/mL, elevated LDH, plasmablastic morphology, or abnormal chromosome 13 * Advanced heart, lung, renal (kidney), or liver disease * Two or more severe symptoms (≥7 on 0-10 scale): pain, tiredness, drowsiness, nausea, bad appetite, shortness of breath, depression, or anxiety 3. Patient can understand spoken or written English 4. Patient receives care in southeast Louisiana

Exclusion criteria

* Known history of receiving specialty palliative care or hospice * Significant psychiatric or other co-morbid disease that would prohibit informed consent or participation in the study * Unlikely to complete any follow-up surveys

Design outcomes

Primary

MeasureTime frameDescription
Aim 1: Palliative Care Knowledge Scale (PaCKS)Post-test of Visit 1, typically day 1Percentage correct on 13 items; higher scores indicate greater knowledge

Secondary

MeasureTime frameDescription
Aim 2a: Palliative Care Attitudes Scale (PCAS-9)Post-test of Visit 1, typically day 1Total score from 0-36; higher scores indicate more positive attitudes
Aim 2b: Palliative Care UtilizationUp to 90 daysUtilization of palliative care (presence/absence)
Aim 3a: Patient-Reported Outcome Measurement Information System (PROMIS) Self-Efficacy for Managing Chronic ConditionsFollow-up at 14, 90, and 180 daysTotal score from 8-40 on 8 items from PROMIS self-efficacy for managing symptoms and self-efficacy for managing emotions items banks; higher scores indicate greater self-efficacy
Aim 3b: PROMIS Emotional DistressFollow-up at 14, 90, and 180 daysTotal score from 8-40 on 8 items from the PROMIS Depression and Anxiety item banks; higher scores indicate greater symptom severity
Aim 3c: Edmonton Symptom Assessment Scale (ESAS)-PhysicalFollow-up at 14, 90, and 180 daysTotal score from 0-60 on 6 ESAS ratings of pain, tiredness, drowsiness, nausea, poor appetite, and difficulty breathing; higher scores indicate greater symptom severity

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMichael Hoerger, PhD, MSCR, MBA

Tulane University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026